S-1: VivoSim Labs Files S-1 for Resale of Shares

VivoSim Labs, Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 9,411,766 shares of common stock.

Summary

• VivoSim Labs, Inc. (formerly Organovo Holdings, Inc.) has filed a Form S-1 registration statement with the SEC.
• The filing pertains to the resale of up to 9,411,766 shares of common stock by a selling stockholder, Armistice Capital Master Fund Ltd.
• These shares are issuable upon the exercise of pre-funded warrants and common warrants issued on July 17, 2026.
• The company has transitioned its business model to focus on providing testing of drugs and drug candidates using 3D human tissue models of liver and intestine.
• This new model leverages New Approach Methodologies (NAM) for toxicology insights, anticipating increased adoption following FDA guidance.
• The company previously focused on developing FXR314 for inflammatory bowel disease (IBD) but sold this program in March 2025 for $10.0 million.
• A milestone payment of $5.0 million was received in July 2026 related to FXR314 development.
• The company's liver toxicology platform demonstrated 87.5% sensitivity and 100% specificity in predicting liver toxicity in a set of challenging cases.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the nature of a resale registration statement, the company's transition from drug development to services, and the presence of a going concern warning, despite positive technological claims.

Positives

• The company has a best-in-class predictive liver toxicology platform with 87.5% sensitivity and 100% specificity.
• The shift to a pharmaceutical and biotechnology services model focused on 3D human tissue testing aligns with anticipated FDA guidance favoring non-animal NAM methods.
• Received a $5.0 million milestone payment in July 2026 related to the previous FXR314 program.
• The company has a clear strategy to offer liver and intestinal toxicology screening services.

Negatives

• The company is a smaller reporting company and has elected to use scaled disclosure, which may limit the detail available.
• The filing includes a going concern warning from the independent registered public accounting firm.
• The company's common stock was trading at $0.386 on July 30, 2026, indicating a low stock price.
• The company previously divested its FXR program, suggesting a strategic pivot away from drug development.

Risks

• Investing in the company's common stock involves a high degree of risk.
• The company's business, financial condition, or results of operations could be materially adversely affected by various risks.
• The occurrence of any of these risks might cause investors to lose all or part of their investment.
• The company is subject to the provisions of Section 203 of the DGCL regulating corporate takeovers.
• The company's authorized but unissued shares of common and preferred stock could be used to discourage takeover attempts.
• The company's classified board structure and advance notice requirements for stockholder actions could discourage unsolicited acquisition proposals.

Future Outlook

The company is focused on providing drug testing services using 3D human tissue models and anticipates accelerated adoption of these NAM models. They also plan to offer investigational toxicology and other applications of their tissue models. A portion of internal research continues to focus on early-stage drug discovery, target validation, and testing compounds for partnering or internal development.

Management Comments

• The company's liver toxicology platform had a best-in-class predictive power, showing 87.5% sensitivity and 100% specificity for a set of challenging liver toxicity cases.
• The company believes its proprietary technologies enable critical complex, multicellular disease models for studying and developing clinically effective drugs.
• The company's new business model reflects the use of its intestinal and liver tox models, expertise, and 3D bioprinting IP portfolio.

Industry Context

StockSavvy.ai notes that VivoSim Labs' strategic pivot towards providing drug testing services using 3D human tissue models aligns with the broader industry trend of adopting New Approach Methodologies (NAM) to reduce reliance on animal testing, as encouraged by regulatory bodies like the FDA. This positions the company to capitalize on the growing demand for more predictive and efficient preclinical drug evaluation.

Corporate Governance

Stakeholder Impact

• Shareholders: The resale of shares by the selling stockholder could increase the supply of shares available in the market, potentially impacting the stock price. The company's strategic shift and financial health are key considerations for investors.
• Employees: The company's focus on services and potential for future growth may impact employee roles and opportunities. The company has various equity incentive plans for employees and directors.
• Creditors: The company's financial condition, as indicated by the going concern warning, is relevant to creditors. The use of proceeds from any cash exercise of warrants for working capital is noted.

Next Steps

• The selling stockholder may offer and sell shares of common stock from time to time.
• The company may amend or supplement the prospectus to reflect changes in the offering.
• The company will continue to file periodic reports with the SEC.

Key Dates

Recommendation

The filing is primarily a resale registration statement, indicating a significant portion of shares may become available for trading. While the company's technological claims in toxicology are positive, the shift from drug development to services, coupled with a going concern warning and a low stock price, suggests caution. A 'hold' recommendation is appropriate pending further clarity on the execution of the new business model and sustained financial improvement.

Keywords

VivoSim Labs, S-1 Filing, Resale of Shares, Common Stock, Warrants, 3D Human Tissue Models, Toxicology Testing, Biotechnology Services